Genedrive PLC Distribution agreement with Beckman Coulter (1217N)
January 28 2021 - 1:00AM
UK Regulatory
TIDMGDR
RNS Number : 1217N
Genedrive PLC
28 January 2021
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulation (EU) No. 596/2014. Upon the publication
of this announcement via the Regulatory Information Service, this
inside information is now considered to be in the public
domain.
genedrive plc
("genedrive" or the "Company")
Distribution agreement with Beckman Coulter Life Sciences for
COVID-19 PCR testing
genedrive plc (AIM: GDR), the near patient molecular diagnostics
company, announces that it has entered into a distribution
agreement with Beckman Coulter Life Sciences ("Beckman Coulter")
for its Genedrive(R) 96 SARS-CoV-2 Kit. The agreement enables
Beckman Coulter to sell and distribute genedrive's high-throughput
COVID-19 PCR Kit in the United States and Europe for use on upper
respiratory viral samples. The agreement is the result of the
collaboration agreement announced in August 2020, under which the
companies worked to develop and validate a fully automated PCR
process for Beckman Coulter's Biomek automated workstation in
conjunction with its RNAdvance Viral XP extraction kit.
The Genedrive(R) 96 SARS-CoV-2 test is ideally suited for use on
the high throughput robotic Biomek i7 instrument. The ready-to-go
nature of the test removes many of the fluid dispensing steps
required in competitor assays, increasing the overall throughput of
the Biomek compared to using a liquid reagent based test
formulation. Full automation of the overall PCR workflow can allow
laboratories to run large numbers of tests over extended working
hours or workstation platforms. Beckman Coulter estimates that this
new turnkey solution could process circa 1,000 PCR samples per
Biomek workstation installed during a standard 8-hour working day,
using just a 0.5 full-time-equivalent in technician time for
processing.
David Budd, CEO of genedrive plc, said: "We are very pleased to
have the partnership of Beckman Coulter in accessing significant
COVID testing opportunities throughout the United States and
Europe, where the incidence of COVID continues to escalate and the
need for high throughout testing solutions remains a priority. The
combination of genedrive and Beckman Coulter products and expertise
provides the Company with a new, innovative, and competitive
solution, and a new sales channel for the American market, which we
did not have previously.
"We are very pleased to now take our initial collaboration and
development agreement to the commercial stage. Beckman Coulter is
an important and significant company in these core geographies,
well suited to promoting, selling, and supporting our
products."
The Companies are planning commercial introduction of the
Genedrive kit from mid February, following commercial and technical
training of the Beckman sale and support organisations.
For further details please contact:
genedrive plc +44 (0)161 989 0245
David Budd: CEO / Matthew Fowler:
CFO
Peel Hunt LLP (Nominated Adviser
and Joint Broker) +44 (0)20 7418 8900
James Steel / Oliver Jackson
finnCap (Joint Broker) +44 (0)20 7220 0500
Geoff Nash / Kate Bannatyne / Alice
Lane
Walbrook PR Ltd (Media & Investor +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Relations)
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About genedrive plc ( http://www.genedriveplc.com )
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Company has assays on market for the detection of
HCV, certain military biological targets, and has tests in
development for tuberculosis (mTB). The Company recently released a
high throughput SARS-CoV-2 assay and has in development a
Genedrive(R) Point of Care version of the assay, both based on
Genedrive(R) chemistry.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRBRGDBXSDDGBR
(END) Dow Jones Newswires
January 28, 2021 02:00 ET (07:00 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2023 to Apr 2024